PATENT CLAIM ANALYSIS

Application Number: 16128419
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["514", "272000"]

Abstract:
The disclosure provides methods for the treatment of Friedreich's ataxia (FRDA), an autosomal recessive ataxia caused by mutation of the FXN gene, by administering to a subject a therapeutically effective amount of etravirine, or a pharmaceutically acceptable salt thereof. Etravirine is demonstrated to increase the levels of frataxin precursor and intermediate and mature forms of frataxin.

Claim (Index 6):
The method of  claim 5 , wherein the mutant FXN gene comprises a mutation in the first intron of the FXN gene.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 97.0
- Lexical Diversity: 1.33333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14862072', '15472852', '13820092', '14034224', '15568961']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7906039891262822
- 35 USC 102 Novelty (BERT): 0.5309502361363971
- Combined Prediction Score: 0.7646386138272937
- Mean Citation Score: 331.807922
- Max Citation Score: 344.77557
- Similarity Product: 211.0578427997196

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test